(Q35653049)

9 August 2017

1 reference

title

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies (English)

1 reference

9 August 2017

1 reference

2

Srdan Verstovsek

1 reference

9 August 2017

Amit Panwalkar

1

1 reference

PubMed ID

14770419

9 August 2017

Francis J Giles

series ordinal

3

1 reference

PubMed ID

14770419

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

9 August 2017

100

1 reference

9 August 2017

657-666

1 reference

9 August 2017

4

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

9 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

21 January 2018

IL-10 in myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Human brain tumor xenografts in nude mice as a chemotherapy model.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

New antitumor substances of natural origin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Activity of rapamycin (AY-22,989) against transplanted tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Tor signalling in bugs, brain and brawn

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Identification of TOR signaling complexes: more TORC for the cell growth engine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Targeting mTOR signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Quick guide: target of rapamycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

RTG-dependent mitochondria to nucleus signaling is negatively regulated by the seven WD-repeat protein Lst8p

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Downstream effectors of oncogenic ras in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Mechanisms and consequences of activation of protein kinase B/Akt

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The mRNA 5' cap-binding protein eIF4E and control of cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Identification of a conserved motif required for mTOR signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Role of S6 phosphorylation and S6 kinase in cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Phosphorylation and activation of p70s6k by PDK1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Modulation of transcription of rRNA genes by rapamycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Drug resistance and drug development in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Clinical development of mammalian target of rapamycin inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The AKT kinase is activated in multiple myeloma tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Survival of acute myeloid leukemia cells requires PI3 kinase activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Mammalian target of rapamycin: a new molecular target for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Epstein-Barr virus and oncogenesis: from latent genes to tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Everolimus in pediatric de nova renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Resistance to rapamycin: a novel anticancer drug

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20026

7 January 2021

Identifiers

DOI

10.1002/CNCR.20026

1 reference

9 August 2017

1 reference

PubMed ID

14770419